) oncology candidate ABT-414 received orphan drug status in the
U.S. and the EU for the treatment of glioblastoma multiforme.
AbbVie is developing ABT-414 with certain components in-licensed
from Life Science Pharmaceuticals, Inc. and Seattle Genetics (
Orphan drug status is granted to treatments being developed for
rare diseases (affecting less than 200,000 people in the U.S. and
up to 5 out of 10,000 people in the EU).
Glioblastoma multiforme is the most common and aggressive type of
malignant primary brain tumor. According to the press release
issued by AbbVie, 2−3 out of 100,000 people in the U.S. and Europe
are diagnosed with glioblastoma multiforme each year, with a
five-year survival rate of only 4% (approximately). After nearly 15
months of diagnosis, patients are found to succumb to their
Currently, ABT-414 is in a phase II program for the treatment of
Considering the limited treatment options for glioblastoma
multiforme, there is urgent need for new treatments in this field.
If successfully developed and commercialized, ABT-414 will boost
the company's portfolio.
Meanwhile, Tocagen Inc.'s Toca 511 in combination with Toca FC is
also under development for the treatment of glioblastoma
We remind investors that AbbVie is working on strengthening its
portfolio. In Jul 2014, the company announced its plans to acquire
Shire plc (
). This deal makes AbbVie the latest to join a string of U.S.
health care companies that have been looking towards overseas
acquisitions to lower their tax rates.
AbbVie will not just lower its taxes through this acquisition; it
will also boost its product portfolio significantly. This
acquisition is very important for the company, which was mainly
dependent on a single drug, Humira, for growth.
AbbVie carries a Zacks Rank #3 (Hold). A better-ranked stock in the
biotech sector is Actelion (
), carrying a Zacks Rank #1 (Strong Buy). Seattle Genetics carries
a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
SHIRE PLC-ADR (SHPG): Free Stock Analysis
ABBVIE INC (ABBV): Free Stock Analysis Report
ACTELION LTD (ALIOF): Get Free Report
SEATTLE GENETIC (SGEN): Free Stock Analysis
To read this article on Zacks.com click here.